Pan-cancer analysis of KEAP1 mutations as biomarkers for immunotherapy outcomes.

Immune checkpoint inhibitors (ICIs) that target programmed cell death protein 1 (PD-1) and its ligand (PD-L1), or cytotoxic T lymphocyte antigen-4 (CTLA-4) elicit durable antitumor responses in multiple cancer types. Yet, only a minority of patients could derive clinical benefit (1).

[1]  Chunyan Wu,et al.  Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma , 2019, Journal of Hematology & Oncology.

[2]  E. V. Van Allen,et al.  Genomic correlates of response to immune checkpoint blockade , 2019, Nature Medicine.

[3]  C. Brennan,et al.  Tumor mutational load predicts survival after immunotherapy across multiple cancer types , 2019, Nature Genetics.

[4]  R. Weinberg,et al.  Understanding the tumor immune microenvironment (TIME) for effective therapy , 2018, Nature Medicine.

[5]  Jun S. Liu,et al.  TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. , 2017, Cancer research.

[6]  Donavan T. Cheng,et al.  Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.

[7]  Kongming Wu,et al.  Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer , 2016, Journal of Hematology & Oncology.

[8]  L. Gandhi,et al.  Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review. , 2016, JAMA oncology.

[9]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[10]  Ash A. Alizadeh,et al.  Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance. , 2017, Cancer discovery.